Epidemiology Non-cholera Vibrio Infections

计划入组 67 人 · 首次发布于 2020 年 6 月 30 日

CV638 ability to protect against homologous Vibrio cholerae 3008 virulent strai

计划入组 120 人

A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children

计划入组 200 人 · 首次发布于 2008 年 9 月 26 日

Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated(Dukoral)

Vibrio cholerae Inaba 48 classical biotype, heat inactivated

Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated

Virios Therapeutics

United States

ULUSLARARASI KIBRIS UNIVERSITESI

country_xt

Tiburio Therapeutics, Inc.

United States

Vibrio vulnificus Expands Northward Along U.S. Atlantic Coast as Climate Change Fuels Spread, Researchers Race to Build Early Warning System

Emergent Vibrio parahaemolyticus Gastroenteritis Outbreaks in New Zealand, 2019–2022: Trans-Pacific Spread of ST36 and Emergence of ST50

Bharat Biotech's Oral Cholera Vaccine 'Hillchol' Successfully Completes Phase III Trials